

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


# **Single Technology Appraisal**

Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma ID5123

### **Provisional Stakeholder List**

Consultees	Commentators (no right to submit or appeal)
Company	General
Astellas Pharma (Zolbetuximab)	All Wales Therapeutics and Toxicology     Centre
<ul><li>Patient/carer groups</li><li>Black Health Agency for Equality</li></ul>	<ul><li>Allied Health Professionals Federation</li><li>Board of Community Health Councils in</li></ul>
Cancer Black Care	Wales
<ul><li>Cancer Equality</li><li>Cancer 52</li></ul>	British National Formulary     Care Quality Commission
<ul><li>Gancer 52</li><li>GIST Cancer UK</li></ul>	<ul><li>Care Quality Commission</li><li>Department of Health, Social Services</li></ul>
GUTS UK	and Public Safety for Northern Ireland
Heartburn Cancer UK     Heartburn Cancer UK	Healthcare Improvement Scotland     Madicines and Healthcare products
<ul><li>Helen Rollason Cancer Charity</li><li>Independent Cancer Patients Voice</li></ul>	<ul> <li>Medicines and Healthcare products Regulatory Agency</li> </ul>
Macmillan Cancer Support	National Association of Primary Care
Maggie's Centres	<ul><li>National Pharmacy Association</li><li>NHS Confederation</li></ul>
<ul><li>Marie Curie</li><li>Ochre</li></ul>	<ul><li>NHS Confederation</li><li>Scottish Medicines Consortium</li></ul>
Oesophageal & Gastric Cancer	Welsh Government
Charity	Welsh Health Specialised Services     Committee
<ul><li>PAWS GIST Clinic</li><li>South Asian Health Foundation</li></ul>	Committee
Specialised Healthcare Alliance	Possible comparator companies
Tenovus Cancer Care	Accord Healthcare (capecitabine, cisplatin, epirubicin, fluorouracil,
Together Support Group	oxaliplatin)
Healthcare professional groups	Bristol-Myers Squibb (nivolumab)
Association of Anaesthetists	<ul><li>Dr. Reddy's Laboratories (capecitabine)</li><li>Glenmark Pharmaceuticals</li></ul>
<ul><li>Association of Cancer Physicians</li><li>Association of Surgeons of Great</li></ul>	(capecitabine)
Britain and Ireland	Hospira UK (cisplatin, fluorouracil,
Association of Upper Gastrointestinal     Surgeons of Croet Pritain and Iroland	<ul><li>oxaliplatin)</li><li>Medac (epirubicin, fluorouracil,</li></ul>
<ul><li>Surgeons of Great Britain and Ireland</li><li>British Association of Surgical</li></ul>	oxaliplatin)
Oncology	Morningside Healthcare (capecitabine)

Provisional stakeholder list for evaluation of zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma ID5123. Issue date: November 2023



Consultees	Commentators (no right to submit or appeal)
<ul> <li>British Geriatrics Society</li> <li>British Institute of Radiology</li> <li>British Oncology Pharmacy Association</li> <li>British Psychosocial Oncology Society</li> <li>British Society of Gastroenterology</li> <li>Cancer Research UK</li> <li>Primary Care Society for Gastroenterology</li> <li>Royal College of Anaesthetists</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Radiologists</li> <li>Royal College of Surgeons</li> <li>Royal College of Surgeons</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiographers</li> <li>UK Clinical Pharmacy Association</li> <li>UK Oncology Nursing Society</li> </ul> Others <ul> <li>Department of Health and Social Care</li> <li>NHS England</li> </ul>	<ul> <li>MSD (pembrolizumab)</li> <li>Pfizer (epirubicin)</li> <li>Sandoz (cisplatin)</li> <li>Seacross Pharmaceuticals (epirubicin, oxaliplatin)</li> <li>Sun Pharma (oxaliplatin)</li> <li>Relevant research groups</li> <li>Cochrane UK</li> <li>Cochrane Gut Group</li> <li>Genomics England</li> <li>Institute of Cancer Research</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> <li>Associated Public Health groups</li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


#### **Definitions:**

## Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for evaluation of zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma ID5123. Issue date: November 2023



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

## Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.